This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| OpenEye Scientific | |
|---|---|
| Name | OpenEye Scientific |
| Industry | Software, Computational Chemistry |
| Founded | 1997 |
| Founder | Anthony Nicholls |
| Headquarters | Santa Fe, New Mexico |
| Products | Omega, ROCS, VIDA, FILTER, EON |
OpenEye Scientific is a company that develops software for molecular modeling, cheminformatics, and computational drug discovery. The company provides tools used by pharmaceutical companies, biotechnology firms, and academic laboratories for ligand-based design, structure-based modeling, and virtual screening. Its offerings have been applied in projects connected to lead discovery, fragment-based drug design, and cheminformatics workflows.
OpenEye Scientific was founded in 1997 in Santa Fe, New Mexico by Anthony Nicholls and collaborators after prior experience at organizations such as Wright-Patterson Air Force Base and collaborations with researchers from University of California, San Francisco, Sandia National Laboratories, and Los Alamos National Laboratory. Early milestones included the release of conformer generation and shape-based comparison tools, developed alongside academic work from groups at Harvard University, Stanford University, and Massachusetts Institute of Technology. Growth through the 2000s paralleled rising investment in computational chemistry at companies like Pfizer, GlaxoSmithKline, and Merck & Co., and the company expanded its product line amid collaborations with institutions such as Scripps Research Institute and European Bioinformatics Institute. In the 2010s the company evolved alongside trends set by initiatives at National Institutes of Health, Wellcome Trust, and public-private consortia exemplified by Innovative Medicines Initiative. The firm’s trajectory culminated in acquisition activity and strategic alignments with larger technology platforms similar to transactions seen with Thermo Fisher Scientific and Schrödinger (company).
The company is known for a suite of software including conformer generators, shape-based virtual screening, and cheminformatics toolkits used by teams at AstraZeneca, Bristol-Myers Squibb, Novartis, and Johnson & Johnson. Core technologies include a fast conformer generator inspired by methods from groups at University of Cambridge and University of Oxford, a shape comparison engine analogous to research from University of California, San Diego groups, and a pharmacophore and scoring framework used in projects at Eli Lilly and Company. Notable product names became integrated into workflows involving molecular docking platforms from GOLD (software) and AutoDock, and visualization pipelines referencing tools developed at Visualization Sciences Group and Schrödinger. The company’s toolkits interoperate with file formats and standards such as those promoted by Protein Data Bank, CIF conventions, and cheminformatics initiatives spearheaded by Open Babel and RDKit contributors. Computational performance improvements track with parallelization research from Argonne National Laboratory and algorithmic advances reported by teams at Lawrence Livermore National Laboratory.
Their algorithms for shape comparison and electrostatic mapping have been cited in studies originating from laboratories at University of Chicago, Yale University, Columbia University, and Johns Hopkins University. Applications include virtual screening campaigns for oncology targets pursued in collaborations with Memorial Sloan Kettering Cancer Center and anti-infective programs aligned with work at Centers for Disease Control and Prevention and Walter Reed Army Institute of Research. The company’s outputs have supported fragment-based drug design efforts like those described in publications from Institute of Cancer Research and fragment libraries developed with contributors linked to Diamond Light Source. Case studies reflect integration into lead optimization programs at Genentech, Roche, and biotechnology startups emerging from incubators such as JLABS and Biolabs. Methodological contributions intersect with cheminformatics research from University of British Columbia, McGill University, and ETH Zurich, and with machine learning approaches advanced at Google DeepMind and Microsoft Research.
The organization operated as a privately held company with leadership including its founder and subsequent executives who had prior affiliations with research institutions and companies like ExxonMobil, Boehringer Ingelheim, and Agilent Technologies. Board advisors and scientific collaborators have included academics from Imperial College London, University of Tokyo, and Duke University. Corporate governance and strategic decisions reflected trends in technology adoption similar to moves by Roche Diagnostics and corporate development approaches used by Illumina. Human capital initiatives saw recruitment from graduate programs at California Institute of Technology, Cornell University, and University of Pennsylvania.
The company established partnerships with pharmaceutical and biotech firms including Celgene, Amgen, and Takeda Pharmaceutical Company for software licensing and computational chemistry services. Collaborative research agreements involved academic centers such as University of North Carolina at Chapel Hill, University of Michigan, and Penn State University. Consortium participation mirrored engagement models used by Structural Genomics Consortium and public-private efforts like Open Targets. Technology integrations connected the company’s offerings with platforms from PerkinElmer, BIOVIA (Dassault Systèmes), and cloud providers such as Amazon Web Services and Microsoft Azure.
The company received recognition within cheminformatics and pharmaceutical informatics communities, with software cited in journals associated with American Chemical Society, Nature Publishing Group, and Elsevier titles. Its methods appeared in conference programs at American Chemical Society National Meeting, Gordon Research Conferences, and ISMB. The impact is evident in adoption by research groups at Broad Institute, Cold Spring Harbor Laboratory, and contract research organizations exemplified by Charles River Laboratories. Overall, the company's technologies influenced virtual screening, lead discovery, and computational chemistry education at institutions like MIT, Harvard Medical School, and UCSF School of Pharmacy.
Category:Cheminformatics companies